First drug approved for treatment of spinal muscular atrophy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

FDA approved Spinraza (nusinersen), the first drug to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

SMA is a genetic disease that causes weakness and muscle wasting because of the loss of lower motor neurons controlling movement. SMA is classified in many types based on age of onset, severity of muscle weakness and symptoms. Spinraza is an injection administered into the fluid surrounding the spinal cord, approved for use across the range of spinal muscular atrophy patients.

The efficacy of Spinraza was demonstrated in a clinical trial including 121 patients (aged < 7 mo at the time of 1st dose) with infantile-onset SMA diagnosed before 6 months of age. Patients were randomized to receive an injection of Spinraza, into the fluid surrounding the spinal cord, or undergo a mock procedure without drug injection (a skin prick). In an interim analysis 40% of patients treated with Spinraza achieved improvement in motor milestones (head control, sitting, ability to kick in supine position, rolling, crawling, standing and walking), whereas none of the control patients did.

The findings of additional open-label uncontrolled clinical studies conducted in symptomatic patients (aged 30 days to 15 yrs at the time of 1st dose) and presymptomatic patients (aged 8 days to 42 days at the time of 1st dose) support the clinical efficacy demonstrated in the controlled clinical trial in infantile-onset patients.

The most common side effects reported in patients...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of VV28F Reinforced Dual Lumen ECMO Catheters by OriGen Biomedical- Extension tube may separate from hub

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA statement on risks of unapproved use of Keytruda (pembrolizumab) for treatment of multiple myeloma

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Piyanping Anti-Itch Lotion by Lucky Mart Inc.: Contain wrong active pharmaceutical ingredient

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Diabetes Infusion Sets by Medtronic -Vent Membrane susceptible to blocking by fluid

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Baby Organic Liquid Formula by Garden of Life: Misleading direction for use

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Activase (alteplase) 100mg by Genentech due to lack of sterility assurance

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Alert- Not to use Alcohol Pads or Benzalkonium Chloride Antiseptic Towelettes by Foshan Flying Medical Products

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Oxytocin compounded with either Lactated Ringers or Lactated Ringers and Dextrose by PharMEDium

Read more
  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of one lot of Vancomycin Hydrochloride for Injection USP, 750 mg/vial by Hospira: Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Doctor Manzanilla Cough & Cold and Allergy & Decongestant Relief Syrup: Contaminated with Burkholderia cepacia

Read more
  • MedWatch Drug Updates
  • no comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Endari (L-glutamine) for sickle cell disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Atar Extension Cables by Oscor- cable malfunction interrupting the pacing system

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Novopen Echo Insulin Delivery Device by Novo Nordisk: Chemical exposure may damage cartridge holder

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of lorazepam oral concentrate, USP 2mg/mL - defect in the dropper markings

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I recall of Zenith Alpha Thoracic Endovascular Graft by Cook Medical – thrombus may form inside the device

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Haegarda (C1 esterase inhibitor) for Hereditary Angioedema

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more